Vera Therapeutics, Inc.
NASDAQ:VERA
41.99 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | -0.952 | -0.635 | 0 | 0 | -0.506 | 0 | 0 | 0 | 0.009 | 0.032 | 0.059 | 0.05 | 0.035 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0.952 | 0.635 | 0 | 0 | 0.506 | 0 | 0 | 0 | -0.009 | -0.032 | -0.059 | -0.05 | -0.035 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 29.311 | 24.669 | 21.952 | 16.1 | 16.231 | 25.108 | 26.676 | 19.656 | 10.112 | 12.549 | 12.753 | 3.564 | 3.235 | 2.932 | 39.844 | 1.969 | 1.954 | 1.439 |
| General & Administrative Expenses
| 8.032 | 7.912 | 6.243 | 5.656 | 5.739 | 6.15 | 6.905 | 5.588 | 4.945 | 4.472 | 3.832 | 3.688 | 2.614 | 1.784 | 1.136 | 0.652 | 1.219 | 1.032 |
| Selling & Marketing Expenses
| 0 | -0.517 | -0.532 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8.032 | 7.395 | 5.711 | 5.656 | 5.739 | 6.15 | 6.905 | 5.588 | 4.945 | 4.472 | 3.832 | 3.688 | 2.614 | 1.784 | 1.136 | 0.652 | 1.219 | 1.032 |
| Other Expenses
| 0.45 | 0.453 | 0.472 | 1.652 | 0.511 | 1.189 | 0.912 | 0.347 | 0.325 | 0.315 | -0.261 | 0 | 0 | 0 | -0.301 | -0.359 | -0.369 | -0.047 |
| Operating Expenses
| 37.343 | 32.064 | 27.663 | 21.756 | 21.97 | 31.258 | 33.581 | 25.244 | 15.057 | 17.021 | 16.585 | 7.252 | 5.849 | 4.716 | 40.98 | 2.621 | 3.173 | 2.471 |
| Operating Income
| -37.343 | -31.112 | -27.028 | -21.756 | -21.97 | -31.258 | -33.581 | -25.244 | -15.057 | -17.021 | -16.585 | -7.252 | -5.849 | -4.716 | -42.56 | -4.037 | -3.173 | -2.471 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.635 | 2.729 | 1.374 | 1.652 | 0.483 | 1.189 | 1.143 | 0.565 | 0.069 | -0.064 | -0.261 | -0.364 | 2.41 | 0.002 | -1.881 | -1.775 | -0.369 | -0.047 |
| Income Before Tax
| -33.708 | -28.383 | -25.654 | -20.104 | -20.162 | -30.069 | -32.438 | -24.679 | -14.853 | -17.085 | -16.846 | -7.611 | -3.437 | -4.714 | -42.874 | -4.46 | -3.604 | -2.474 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.995 | 0.001 | 1.442 | 2.396 | -0.315 | 0.001 | -0.565 | 0.559 | 0.064 | 0.001 | 0.359 | -2.412 | -0.002 | 2.223 | 0.423 | 0.431 | 0.003 |
| Net Income
| -33.708 | -28.383 | -25.655 | -20.104 | -20.162 | -29.754 | -32.439 | -24.114 | -14.853 | -17.149 | -16.847 | -7.611 | -3.437 | -4.714 | -42.875 | -4.46 | -3.604 | -2.474 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.62 | -0.56 | -0.58 | -0.45 | -0.46 | -0.79 | -1.17 | -0.89 | -0.55 | -0.71 | -0.79 | -0.36 | -0.33 | -0.23 | -2.09 | -1.09 | -0.88 | -0.61 |
| EPS Diluted
| -0.62 | -0.56 | -0.58 | -0.45 | -0.46 | -0.79 | -1.17 | -0.89 | -0.55 | -0.71 | -0.79 | -0.36 | -0.33 | -0.23 | -2.09 | -1.09 | -0.88 | -0.61 |
| EBITDA
| -35.848 | -32.064 | -27.663 | -21.756 | -19.22 | -31.258 | -31.775 | -24.33 | -14.469 | -16.671 | -16.585 | -7.188 | -5.797 | -4.679 | -41.279 | -2.307 | -3.429 | -2.342 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |